Quantification of linezolid in serum by LC-MS/MS using semi-automated sample preparation and isotope dilution internal standardization

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 3, 2014, Pages 381-389

  Zander, Johannes ^a   Maier, Barbara ^a   Zoller, Michael ^a   Teupser, Daniel ^a   Vogeser, Michael ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Linezolid; Liquid chromatography tandem mass spectrometry (LC MS MS); Mass spectrometry; On line solid phase extraction; Serum; Therapeutic drug monitoring

Indexed keywords

LINEZOLID;

ANALYTIC METHOD; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG STABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; ISOTOPE DILUTION ASSAY; ISOTOPE DILUTION INTERNAL STANDARDIZATION; LIQUID CHROMATOGRAPHY; LIVER TOXICITY; MEASUREMENT ACCURACY; MEASUREMENT ERROR; PRECIPITATION; PRIORITY JOURNAL; PROTEIN PRECIPITATION; QUANTITATIVE ASSAY; RELIABILITY; REPRODUCIBILITY; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; VALIDITY;

ACETAMIDES; ANALYTIC SAMPLE PREPARATION METHODS; AUTOMATION; BLOOD CHEMICAL ANALYSIS; CHROMATOGRAPHY, LIQUID; HUMANS; OXAZOLIDINONES; RADIOISOTOPE DILUTION TECHNIQUE; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

EID: 84896138650     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0594     Document Type: Article

References (44)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
2. Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 2007;33:606-18.
3. Karlsson S, Varpula M, Ruokonen E, Pettila V, Parviainen I, Ala-Kokko TI, et al. Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med 2007;33:435-43.
4. Martin CM, Priestap F, Fisher H, Fowler RA, Heyland DK, Keenan SP, et al. A prospective, observational registry of patients with severe sepsis: the Canadian Sepsis Treatment and Response Registry. Crit Care Med 2009;37:81-8.
5. Quenot JP, Binquet C, Kara F, Martinet O, Ganster F, Navellou JC, et al. The epidemiology of septic shock in French intensive care units: the prospective multicentre cohort EPISS study. Crit Care 2013;17:R65.
6. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-74.
7. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-96.
8. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005;44:1009-34.
9. Reinhart K, Brunkhorst FM, Bone HG, Bardutzky J, Dempfle CE, Forst H, et al. Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv-und Notfallmedizin (DIVI)). Ger Med Sci 2010;8:Doc14.
10. DeRyke CA, Lodise TP, Rybak MJ, McKinnon PS. Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest 2005;128:1414-22.
11. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008;8:53-66.
12. McKenzie C. Antibiotic dosing in critical illness. J Antimicrob Chemother 2011;66(Suppl 2):ii25-31.
13. Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother 2013;68:4-11.
14. Henwood CJ, Livermore DM, Johnson AP, James D, Warner M, Gardiner A, et al. Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. J Antimicrob Chemother 2000;46:931-40.
15. Noskin GA, Siddiqui F, Stosor V. Hacek D, Peterson LR. In-vitro activities of linezolid against important Gram-positive bacterial pathogens including vancomycin-resistant Enterococci. Antimicrob Agents Chemother 1999;43:2059-62.
16. Cepeda JA, Whitehouse T, Cooper B, Hails J, Jones K, Kwaku F, et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicenter study. J Antimicrob Chemother 2004;53:345-55.
17. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003;42:1411-23.
18. Smith PF, Birmingham MC, Noskin GA, Meagher AK, Forrest A, Rayner CR, et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann Oncol 2003;14:795-801.
19. Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. J Infect 2009;59(Suppl 1):S59-74.
20. Cattaneo D, Orlando G, Cozzi V, Cordier L, Baldelli S, Merli S, et al. Linezolid plasma concentrations and occurrence of drug-related hematological toxicity in patients with Gram-positive infections. Int J Antimicrob Agents 2013;41:586-9.
21. Adembri C, Fallani S, Cassetta MI, Arrigucci S, Ottaviano A, Pecile P, et al. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 2008;31:122-9.
22. Dong H, Wang Y, Dong Y, Lei J, Hao L, You H, et al. Clinical pharmacokinetic/pharmacodynamics profile of linezolid in severely ill intensive care unit patients. Int J Antimicrob Agents 2001;38:296-300.
23. Pea F, Fulanut M, Pergiorgieo C, Cristini F, Zamparini E, Franceschi L, et al. Therapeutic drug monitoring of linezolid: a restrospective monocentric analysis. Antimicrob Agents Chemother 2010;54:4605-10.
24. Bodmann Klaus-Friedrich GB. Empfehlungen zur kalkulierten parenteralen Intitialtherapie bakterieller Erkrankungen bei Erwachsenen Update. Paul-Ehrlich-Gesellschaft 2010; Chemother J 2010;19:179-255.
25. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637.
26. Borner K, Borner E, Lode H. Determination of linezolid in human serum and urine by high-performance liquid chromatography. Int J Antimicrob Agents 2001;18:253-8.
27. Peng GW, Stryd RP, Murata S, Igarashi M, Chiba K, Aoyama H, et al. Determination of linezolid in plasma by reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal 1999;20:65-73.
28. Tobin CM, Sunderland J, White LO, MacGowan AP. A simple, isocratic high-performance liquid chromatography assay for linezolid in human serum. J Antimicrob Chemother 2001;48:605-8.
29. Han M, Jun SH, Lee JH, Park KU, Song J, Song SH. Method for simultaneous analysis of nine second-line anti-tuberculosis drugs using UPLC-MS/MS. J Antimicrob Chemother 2013;68:2066-73.
30. Harmelink IM, Alffenaar JC, Wessels AM, Greijdanus B, Uges DR. A rapid and simple liquid chromatography-tandem mass spectrometry method for the determination of linezolid in human serum. EJHP Science 2008;14:3-7.
31. Vlase L, Muntean D, Cuciureanu M, Cuciureanu R, Gocan S. High-throughput determination of linezolid in human plasma by liquid chromatography-tandem mass spectrometry. J Liq Chromatogr Relat Technol 2011;34:436-45.
32. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 2003;75:3019-30.
33. Klee GG. Establishment of outcome-related analytic performance goals. Clin Chem 2010;56:714-22.
34. Richtlinie der Bundesaerztekammer zur Qualitätssicherung laboratoriumsmedizinischer Untersuchungen. Dt Aerzteblatt 2008;105:C301-13.
35. Westgard QC. Rilibak: quality goals the German way. Available from: http://www.westgard.com/rilibak-2.htm. Accessed 23 July, 2013.
36. Colin P, De Bock L, T'jollyn H, Boussery K, Van Bocxlaer J. Development and validation of a fast and uniform approach to quantify ®-lactam antibiotics in human plasma by solid phase extraction-liquid chromatography-electrospray-tandem mass spectrometry. Talanta 2013;103:285-93.
37. Szultka M, Krzeminski R, Szeliga J, Jackowski M, Buszewski B. A new approach for antibiotic drugs determination in human plasma by liquid chromatography-mass spectrometry. J Chromatogr A 2013;1272:41-9.
38. Vu DH, Bolhuis MS, Koster RA, Greijdanus B, de Lange WC, van Altena R, et al. Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrugresistant tuberculosis. Antimicrob Agents Chemother 2012;56:5758-63.
39. Phillips OA, Abdel-Hamid ME, Al-Hassawi NA. Determination of linezolid in human plasma by LC-MS-MS. Analyst 2001;126:609-14.
40. Stokvis E, Rosing H, Beijnen JH. Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: necessity or not? Rapid Commun Mass Spectrom 2005;19:401-7.
41. Food and Drug Administration. FDA guidance for industry: bioanalytical method validation. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2001.
42. Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother 2011;66(Suppl 4):iv7-15.
43. Euopean committee of antimicrobial susceptibility testing. Available from: http://www.eucast.org/mic-distributions/. Accessed 18 July, 2013.
44. Stalker DJ, Jungbluth GL, Hopkins NK, Batts DH. Pharmacokinetics and tolerance of single-and multipledose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 2003;51: 1239-46.